The Cancer Letter highlights UC kidney cancer research

The Cancer Letter highlighted the University of Cincinnati Cancer Center’s Maria Czyzyk-Krzeska's new NIH-funded research that will investigate how copper contributes to the advancement and recurrence of clear cell renal cell carcinoma (ccRCC).

Research has found that increased accumulation of copper is associated with worse outcomes for patients with ccRCC, the most common type of kidney cancer.

“That indicated to us that copper has a potential driving effect in tumor progression of clear cell renal cell carcinoma,” said Czyzyk-Krzeska, a University of Cincinnati Cancer Center researcher and professor in the Department of Cancer Biology in UC’s College of Medicine.

The study will seek to identify the mechanisms that allow ccRCC cells to take up more copper, copper’s metabolic effects on the tumor cells and whether any of the copper-specific features of the tumor cells have vulnerabilities that can open up new treatments for ccRCC. 

“There are essentially two or three major lines of treatment for kidney cancer, but ultimately there’s always a group of tumors that are not responsive or recur” said Czyzyk-Krzeska. “We hope what we find is going to provide opportunities for new treatments.”

Read The Cancer Letter article.

Read more about the research.

Featured photo at top of periodic table highlighting copper. Photo/HT Ganzo/iStock.

Related Stories

2

CCM welcomes new film and media scoring faculty member J.R. Paredes

May 20, 2026

UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of J.R. Paredes as CCM's new Assistant Professor of Film and Media Scoring. His faculty appointment officially begins on Aug. 15, 2026. Paredes is a composer, music producer and audio post-production specialist whose work spans film, television and commercial music. His credits include original scores for feature films and series distributed on platforms such as Apple TV+ and Prime Video, as well as extensive work in sound design and mixing for film and media.

3

6 ways starting a GLP-1 medication could affect your emotions

May 20, 2026

When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.